Блог – PharmCAT.NET

PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Найти:

Свежие записи

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Human medicines European public assessment report (EPAR): Vildagliptin / Metformin hydrochloride Accord, vildagliptin / metformin hydrochloride, Diabetes Mellitus, Type 2, Date of authorisation: 24/03/2022, Revision: 2, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
Don’t Use Products Marketed to Treat Molluscum, a Common Skin Condition
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
Novel Drug Approvals for 2022
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
Drug Trials Snapshot: PYRUKYND
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
Human medicines European public assessment report (EPAR): Empliciti, elotuzumab, Multiple Myeloma, Date of authorisation: 11/05/2016, Revision: 12, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
Strides Pharma Science Limited - 576722 - 05/23/2023
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
Strides Pharma Science Limited - 576722 - 07/01/2019
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By Center for Drug Evaluation and Research
Human medicines European public assessment report (EPAR): Armisarte (previously Pemetrexed Actavis), pemetrexed, Carcinoma, Non-Small-Cell Lung;Mesothelioma, Date of authorisation: 18/01/2016, Revision: 13, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
Cali Botanicals, LLC - 575320 - 06/11/2019
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By Center for Drug Evaluation and Research
IceRx - 1111111 - 10/09/2018
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
FDA and NIH/NCI Center for Cancer Research: Advancing Drug Development in Myelodysplastic Syndromes - 05/16/2023
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
Human medicines European public assessment report (EPAR): Rapilysin, reteplase, Myocardial Infarction, Date of authorisation: 29/08/1996, Revision: 27, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
Human medicines European public assessment report (EPAR): Sildenafil Actavis, sildenafil, Erectile Dysfunction, Date of authorisation: 10/12/2009, Revision: 16, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
Human medicines European public assessment report (EPAR): Gilenya, fingolimod, Multiple Sclerosis, Date of authorisation: 17/03/2011, Revision: 35, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
Guidance Snapshot Pilot
Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.